Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma

BACKGROUND: A phase II trial of pasireotide was performed to assess its efficacy and safety in advanced or metastatic hepatocellular carcinoma (HCC). PATIENTS AND METHODS: Patients with advanced HCC and Child–Pugh score ≤7 received pasireotide LAR 60 mg intramuscularly every 28 days. Primary endpoin...

Descripción completa

Detalles Bibliográficos
Autores principales: Feun, Lynn G, Wangpaichitr, Medhi, Li, Ying-Ying, Kwon, Deukwoo, Richman, Stephen P, Hosein, Peter J, Savaraj, Niramol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769585/
https://www.ncbi.nlm.nih.gov/pubmed/29392123
http://dx.doi.org/10.2147/JHC.S153672

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769585/
https://www.ncbi.nlm.nih.gov/pubmed/29392123
http://dx.doi.org/10.2147/JHC.S153672

Ejemplares similares